Filing Flows › Boston Scientific (BSX) › Guidance & outlook
Boston Scientific (BSX) guidance and outlook
Boston Scientific (BSX) lowered its guidance on Oct 28, 2026: Revenue +4.25% for FY2026; EPS $3.16–$3.18 for Q4 2026. Boston Scientific's 10-Q filed Nov 2, 2026 makes 11 forward-looking statements, 3 of them new and 4 no longer said since the filing before.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | +4.25% | lowered |
| EPS | Q4 2026 | $3.16–$3.18 | new |
From the earnings release filed Oct 28, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 2, 2026
- We remain committed to advancing medical technologies and investing in meaningful R&D projects across our businesses.
- The increase in R&D expenses in both periods was primarily driven by investments across our businesses in order to maintain a pipeline of products that we believe will contribute to future sales growth.
- new · The 2026 Restructuring Plan is intended to support our efforts to drive sustained cost efficiencies and enable continued growth by ensuring that we are structured and resourced to support our strategic priorities.
- new · We expect a portion of the savings to be reinvested in strategic growth initiatives.
- updated · In the first nine months of 2026, the principal reason for the difference between our tax rate from continuing operations and our reported tax rate relates to a discrete tax benefit of $383 million to reflect a change in the anticipated future tax rate at which we expect to recover certain capitalized expenses.
- new · We have evaluated the Organization for Economic Cooperation and Development (OECD)'s Pillar Two framework including all issued guidance.
- We plan to fund the transaction consideration through a combination of cash on hand and newly issued debt in an aggregate amount equal to approximately $11.000 billion, and the remaining portion of the transaction consideration will be paid in shares of our common stock.
- The Penumbra business will be integrated into our Cardiovascular division.
- • Restructuring and restructuring-related net charges (credits) - These adjustments primarily represent severance and other compensation-related charges, fixed asset write-offs, contract cancellations, project management fees, facility shut down costs, costs to transfer manufacturing lines between geographically dispersed facilities and other direct costs associated with our restructuring plans.
- Restructuring plans take place over a defined timeframe and have a distinct project timeline that requires, and begins subsequent to, approval by our Board of Directors.
- Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources.
Boston Scientific's latest quarter
Boston Scientific, Q3 2026: revenue $5.1B (+1% year over year), operating margin 16.1%, net earnings $580M, operating cash flow $1.0B. The chart follows the revenue to costs, profit and cash.
Questions
Did Boston Scientific raise or lower its guidance?
Boston Scientific (BSX) lowered its guidance on Oct 28, 2026: Revenue +4.25% for FY2026; EPS $3.16–$3.18 for Q4 2026.
What does Boston Scientific expect?
The 2026 Restructuring Plan is intended to support our efforts to drive sustained cost efficiencies and enable continued growth by ensuring that we are structured and resourced to support our strategic priorities. We expect a portion of the savings to be reinvested in strategic growth initiatives. In the first nine months of 2026, the principal reason for the difference between our tax rate from continuing operations and our reported tax rate relates to a discrete tax benefit of $383 million to reflect a change in the anticipated future tax rate at which we expect to recover certain capitalize
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.